Agreement between the results of the HepaTrio test and the CAP/CTM HBV and HCV assays.

<p>Abbreviations: CAP/CTM, Cobas® AmpliPrep/Cobas® TaqMan®; HBV, hepatitis B virus; HCV, hepatitis C virus; CI, confidence interval.</p><p>The overall concordance rate between the results from the HepaTrio and the CAP/CTM assays for the detection of HBV along with HCV was 94.14%.</p

Results of the HepaTrio and the Cobas® AmpliPrep/Cobas® TaqMan® (CAP/CTM) HBV and HCV tests.

<p>For discrepant cases between the HepaTrio and the CAP/CTM tests, medical records including the results of serologic tests were reviewed. TP, true positive; FN, false negative; FP, false positive; TN, true negative.</p

Summary of discrepant cases between the HepaTrio and the CAP/CTM assays.

<p>Abbreviations: CAP/CTM, Cobas® AmpliPrep/Cobas® TaqMan®; HBV, hepatitis B virus; HCV, hepatitis C virus; HAV, hepatitis A virus; PCR, polymerase chain reaction; Pos, positive; Neg, negative; NT, not tested; Ind, indeterminate.</p>a<p>Serologic test results between one month before and after sample collection were referenced when the results were consistent at two or more separated time points.</p>b<p>Follow-up CAP/CTM HBV or HCV tests within a month.</p

Sensitivities and specificities of the HepaTrio test and the CAP/CTM assays for detecting HBV and HCV infections.

<p>Abbreviations: CAP/CTM, Cobas® AmpliPrep/Cobas® TaqMan®; HBV, hepatitis B virus; HCV, hepatitis C virus; CI, confidence interval.</p>a<p>Sensitivity and specificity were calculated after excluding the cases with indeterminate final diagnosis (See <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0049106#pone-0049106-t002" target="_blank">Table 2</a>).</p>b<p>The diagnostic performance was estimated on the assumption that the evaluated assay yielded correct results for the indeterminate cases.</p

Diagnostic performance of the HepaTrio test for detecting HBV and HCV infections from a total of 100 hemodialysis patients.

<p>Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; PPV, positive predictive value; NPV, negative predictive value; LR, likelihood ratio.</p>a<p>Data are shown as % (95% confidence interval).</p

Data_Sheet_1_Establishment of muscle mass-based indications for the cystatin C test in renal function evaluation.docx

BackgroundWe aimed to suggest muscle mass-based criteria for using of the cystatin C test for the accurate estimated glomerular filtration rate (eGFR).Materials and methodsWe recruited 138 Korean subjects and evaluated eGFRcr (derived from Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) based on creatinine) was compared to eGFRcys based on cystatin C as the reference value. The skeletal muscle mass index (SMI) by bioelectrical impedance analysis (BIA) was used as representative of muscle mass. Calf circumference (CC) was also evaluated. We defined the patients by eGFRcr as those with values of eGFRcr ≥ 60 mL/min/1.73 m2 but eGFRcys 2 as the detection of hidden renal impairment (DHRI). Cut-off values were determined based on muscle mass for the cases of DHRI suggesting the criteria of cystatin C test in renal function evaluation.ResultsWe confirmed significant negative correlation between %difference of eGFRcr from eGFRcys and SMI (r, −0.592 for male, −0.484 for female) or CC (r, −0.646 for male, −0.351 for female). SMI of 7.3 kg/m2 for males and 5.7 kg/m2 for females were suggested to be significant cutoffs for indication of cystatin C test. We also suggested CC would be valuable for cystatin C indication.ConclusionWe suggested the muscle mass-based objective criteria relating to SMI and CC that would indicate the use of cystatin C to evaluate renal function test in sarcopenic cases. Our results highlight the importance of muscle mass-based selection of renal function.</p